Table 1. Current status of clinical trials against Chagas disease.

Drug	Current use	Trialed for	Target	Stage (notified status)	Ref.
BNZ	Early and acute Chagas	Chronic Chagas cardiomyopathy	DNA damage	Phase III BENEFIT trial of a cohort of 1,000 patients that includes healthy volunteers (unknown).	[13]
NFX	Early and acute Chagas	Bioequivalence of two drug formulations	DNA damage	Phase I (recruiting).	[14]
POS	Antifungal	All stages	CYP51	Phase II (completed).	[15]
POS	Antifungal	Asymptomatic chronic stage	CYP51	Phase II Merck Sharp & Dohme Corp. sponsored trial, includes a combined POS + BNZ test group (ongoing but not recruiting).	[16]
E1224	Ravuconazole antifungal pro-drug awaiting approval	All stages	CYP51	Phase II DNDi sponsored study in Bolivia (unknown).	[17]
Amiodarone	Heart arrythmia	Symtomatic Chagas cardiomyopathy	Inhibition of ergosterol synthesis and Ca2+ homeostasis disruption	Use of amiodarone as comparator of implantable cardioverter defibrillator (ICD). Phase not specified (not yet recruiting).	[18]
Carvedilol	Heart failure	Symtomatic Chagas cardiomyopathy	Beta-blocker	Phase IV to evaluate safety and efficay after renin angiotensin system inhibitors administration (completed).	[19]
Bisoprolol	Alleviate progression to heart failure	Symtomatic Chagas cardiomyopathy	Beta-blocker	Phase III (completed).	[20]